HEARTCARE-B (06609) has released its annual results for 2025. The financial report shows that the company generated revenue of 408 million yuan during the period, a year-on-year increase of 46.9%. At the same time, the company maintained a gross profit margin above 70%, with net profit reaching 83.34 million yuan, marking a significant turnaround from a loss to a profit compared to the previous year. Furthermore, the company's cash flow continued to improve, with operating cash flow reaching 155 million yuan, demonstrating strong internal growth capabilities. Against the backdrop of ongoing volatility in the secondary market, HEARTCARE-B's robust performance has undoubtedly reassured investors. Since September of last year, influenced by market liquidity and multiple external factors, the Hong Kong stock market's medical device sector has experienced continuous fluctuations, with the Hang Seng Healthcare Index declining by nearly 30% during the period. This shift reflects not just simple capital rotation but a structural change in market preferences, as investors are increasingly willing to pay a premium for clear value realization. On the day following the earnings release, HEARTCARE-B's stock price rose by nearly 8% in early trading, significantly outperforming the Hang Seng Index and the Hang Seng Healthcare Index, indicating strong market recognition of the company's annual results and fundamental performance. Thanks to years of accumulation in innovation, research, and commercialization, HEARTCARE-B has now evolved from focusing on neurointerventional business to emphasizing differentiated therapeutic devices, entering a "Phase 2.0" driven by therapeutic products. According to the annual report, HEARTCARE-B's strong growth, resilience, and internal growth capabilities align with current investment trends in the secondary market, establishing a key anchor for the company's stock price to lead a rebound. The "Three Pillars" are accelerating the realization of innovative value. As a leading innovative medical device company in the global commercialization acceleration phase, the core value anchor for HEARTCARE-B in 2025 lies in its transition from Phase 1.0, which relied on breakthrough products, to Phase 2.0, where the "Three Pillars" centered on therapeutic products drive accelerated value realization. As the first interventional medical device company in China to offer a one-stop solution for stroke treatment and prevention, HEARTCARE-B has been committed to evolving its neurointerventional business toward differentiated therapeutic devices. The significant improvement in revenue structure and accelerated profitability growth in 2025 concretely reflect the synergistic development of its business segments. In 2025, the ischemic stroke business continued to play a foundational role, with annual revenue growing by 31.8% year-on-year. The steady growth of this cash cow business is underpinned by the continuous iteration of the company's ischemic product portfolio. During the period, HEARTCARE-B's differentiated intracranial thrombus aspiration catheter gained widespread clinical recognition, with its large-lumen aspiration and cascade aspiration technology (CATCH) receiving a Class I recommendation in the 2025 Chinese Expert Consensus on Endovascular Treatment for Acute Ischemic Stroke. This clear clinical endorsement has substantially accelerated the product's hospital adoption. By the end of the reporting period, the product had entered over 450 hospitals, with a penetration rate of 26% in leading hospitals, driving a sales volume increase of approximately 300%. Beyond the stable performance of its cash cow business, HEARTCARE-B's hemorrhagic stroke business showed "significant incremental growth" in 2025, emerging as another highlight. With the successive launches of its intracranial stents, embolization coils, and flow diversion devices, the company has established a "complete domestic aneurysm treatment solution" and entered a volume growth cycle in 2025, achieving a remarkable revenue increase of 223.2% year-on-year. Among these, the heavyweight intracranial stent, designated as an innovative medical device by the NMPA, was adopted by approximately 500 hospitals in its first commercial year, rapidly boosting the market share of embolization coils. The approval of the flow diversion device during the period further completed the puzzle for HEARTCARE-B's hemorrhagic business. In the interventional access business, driven by the significant scale-up of its star product, the vascular closure device, which entered over 1,800 hospitals and saw annual clinical usage exceed 200,000 units, HEARTCARE-B achieved single-product revenue exceeding 100 million yuan, becoming a key contributor to earnings. Simultaneously, the company is actively advancing the development and commercialization of its second-generation vascular closure device, strengthening its leading position in this field by managing both current and next-generation products. It is evident that, propelled by strong regulatory and commercialization capabilities, HEARTCARE-B's differentiated innovation is translating into substantial commercial outcomes. The synergistic resonance across multiple business segments not only solidifies the company's foundation in innovation and commercialization but also gives investors confidence that upcoming pipeline products can replicate the successful commercialization path of HEARTCARE-B's existing flagship lines, sustaining a virtuous cycle of innovation and value creation. Refined operations enhance safety margins. For HEARTCARE-B, the synergistic growth across business segments and the scale effects from commercialization efforts resulted in operating cash flow of 155 million yuan during the period, with cash and deposits totaling 786 million yuan. The achievement of annual profitability for the first time also indicates that HEARTCARE-B has steadily entered a "innovation-profitability" virtuous cycle. This success is underpinned by comprehensive refined operations spanning sales to research and development. A key manifestation of refined operations in the reporting period was the continuous improvement in the company's expense structure. The financial report shows that the sales and administrative expense ratio decreased from 49.6% in 2024 to 45.8% in 2025. In terms of R&D expenses, as innovation-commercialization conversion capabilities improved and key pipeline products advanced to more mature and certain late-stage development, the company maintained overall R&D expenditure at around 10% through refined management. Additionally, refined operations accelerated product scaling and process maturity, reflected in the steady improvement of profit quality: the gross profit margin increased from 65.4% in 2024 to 70.9% in 2025, a rise of 5.5 percentage points. Multiple catalysts poised for convergence. The innovative pharmaceutical and medical device sector in Hong Kong stocks is experiencing a collective surge, driving the Hang Seng Healthcare Index up nearly 10% over the past seven days. This rally is not driven by short-term sentiment but by the culmination of long-term R&D efforts entering a value realization phase, coupled with the集中 release of positive sales performance. Under this logic, the secondary market has begun to anticipate targets with both impressive earnings and multiple near-term catalysts, with HEARTCARE-B being one such example. Over the past seven days, HEARTCARE-B's stock price has climbed significantly, with a cumulative increase of 13.5%, clearly outperforming the index. This reflects investors' early "bets" on the company's upcoming catalysts in overseas expansion, advanced technology development, and capital market initiatives. In terms of overseas expansion, existing achievements show that during the reporting period, HEARTCARE-B's thrombectomy stent, balloon occlusion catheter, distal access catheter, and microcatheter obtained CE or FDA certifications, securing 56 registrations in 13 other countries or regions. This is reflected financially in a 101.3% year-on-year surge in overseas market revenue in 2025. While enhancing domestic market share, HEARTCARE-B is actively expanding overseas, with new growth engines beginning to take shape. The company's overseas business is progressing orderly, with product registrations advancing steadily. To date, HEARTCARE-B is conducting over 130 product registration projects in 29 other countries or regions, continuously broadening its sales channels. During the earnings conference, management set a clear target for overseas business to contribute 10% of revenue by 2028. In advanced technology布局, HEARTCARE-B's investment in brain-computer interface (BCI) is undoubtedly a major highlight. As one of the earliest medical device companies in China to venture into BCI, HEARTCARE-B is now at the forefront of the domestic BCI landscape. In December last year, the company's "Interventional Brain-Computer Interface System for Motor Dysfunction" project was selected for the 2025 AI Medical Device Innovation Task List. At a recent investor day, HEARTCARE-B not only presented its technical approach for the interventional BCI system but also announced the completion of multiple animal trials, with key functionalities validated. The company plans to conduct the first human clinical trial in 2026 and submit a registration application in 2028. From a market perspective, institutions like McKinsey project the global market size for medical BCI applications to reach $40 billion to $145 billion between 2030 and 2040. In this emerging blue ocean market, HEARTCARE-B is poised to build a technological moat for the next 5-10 years, leveraging its first-mover advantage and deep technical expertise to capitalize on the growth potential of this multi-billion-dollar赛道. In conclusion, from a capital and market perspective, the previous prolonged adjustment in the innovative pharmaceutical and device sector was partly attributable to weak liquidity in the Hong Kong market. However, during this secondary market correction, the industry has reached an inflection point, transitioning from "quantitative change" to "qualitative change" and from the "investment phase" to the "harvest phase." This has created a significant divergence between the stock performance and strong fundamentals of leading innovative companies like HEARTCARE-B. Notably, HEARTCARE-B is one of the few innovative medical device companies under Hong Kong's Chapter 18A that has consistently rewarded investors through share buybacks. Over the past year, the company conducted 30 share repurchases, buying back nearly 1 million shares totaling approximately 60 million HKD, underscoring its commitment to shareholder returns. It is also reported that the company plans to submit an application for a listing on the A-share STAR Market this year, aiming to enhance shareholder returns and stock liquidity by accessing the domestic capital market. Against this backdrop, considering that HEARTCARE-B's current valuation has entered a significantly undervalued range, once market sentiment stabilizes and a sector trend reversal is confirmed, the company's stock price is expected to lead the way out of volatility, demonstrating considerable upward potential to investors.